98 related articles for article (PubMed ID: 36679926)
1. Alterations in Th17 Cells and Non-Classical Monocytes as a Signature of Subclinical Coronary Artery Atherosclerosis during ART-Treated HIV-1 Infection.
Wiche Salinas TR; Zhang Y; Gosselin A; Rosario NF; El-Far M; Filali-Mouhim A; Routy JP; Chartrand-Lefebvre C; Landay AL; Durand M; Tremblay CL; Ancuta P;
Cells; 2024 Jan; 13(2):. PubMed ID: 38247848
[TBL] [Abstract][Full Text] [Related]
2. A Blood Immunological Signature of Subclinical Coronary Artery Atherosclerosis in People Living with HIV-1 Receiving Antiretroviral Therapy.
Wiche Salinas TR; Zhang Y; Gosselin A; Do Rosario NF; El-Far M; Filali-Mouhim A; Routy JP; Chartrand-Lefebvre C; Landay AL; Durand M; Tremblay CL; Ancuta P;
bioRxiv; 2023 Dec; ():. PubMed ID: 38187644
[TBL] [Abstract][Full Text] [Related]
3. Plasmatic HIV-1 soluble gp120 is associated with immune dysfunction and inflammation in ART-treated individuals with undetectable viremia.
Benlarbi M; Richard J; Bourassa C; Tolbert WD; Chartrand-Lefebvre C; Gendron-Lepage G; Sylla M; El-Far M; Messier-Peet M; Guertin C; Turcotte I; Fromentin R; Verly MM; Prévost J; Clark A; Mothes W; Kaufmann DE; Maldarelli F; Chomont N; Bégin P; Tremblay C; Baril JG; Trottier B; Trottier S; Duerr R; Pazgier M; Durand M; Finzi A; ;
medRxiv; 2023 Aug; ():. PubMed ID: 37645879
[TBL] [Abstract][Full Text] [Related]
4. Distinct Inflammatory Phenotypes are associated with subclinical and clinical Cardiovascular disease in People living with HIV.
McGettrick P; Tinago W; O'Brien J; Miles S; Lawler L; Garcia-Leon A; Mahon N; Lambert J; Sheehan G; Landay A; Sabin CA; Cotter AG; Mallon PWG; ;
J Infect Dis; 2024 Jan; ():. PubMed ID: 38214571
[TBL] [Abstract][Full Text] [Related]
5. Deep immune B and plasma cell repertoire in non-small cell lung cancer.
Patel AJ; Khan N; Richter A; Naidu B; Drayson MT; Middleton GW
Front Immunol; 2023; 14():1198665. PubMed ID: 37398676
[TBL] [Abstract][Full Text] [Related]
6. Inflammation in HIV and Its Impact on Atherosclerotic Cardiovascular Disease.
Obare LM; Temu T; Mallal SA; Wanjalla CN
Circ Res; 2024 May; 134(11):1515-1545. PubMed ID: 38781301
[TBL] [Abstract][Full Text] [Related]
7. Anti-inflammatory role of APRIL by modulating regulatory B cells in antigen-induced arthritis.
Carvalho-Santos A; Ballard Kuhnert LR; Hahne M; Vasconcellos R; Carvalho-Pinto CE; Villa-Verde DMS
PLoS One; 2024; 19(5):e0292028. PubMed ID: 38691538
[TBL] [Abstract][Full Text] [Related]
8. NR4A Expression by Human Marginal Zone B-Cells.
Doyon-Laliberté K; Chagnon-Choquet J; Byrns M; Aranguren M; Memmi M; Chrobak P; Stagg J; Poudrier J; Roger M
Antibodies (Basel); 2019 Oct; 8(4):. PubMed ID: 31614541
[TBL] [Abstract][Full Text] [Related]
9. The BAFF/APRIL system: an important player in systemic rheumatic diseases.
Mackay F; Sierro F; Grey ST; Gordon TP
Curr Dir Autoimmun; 2005; 8():243-65. PubMed ID: 15564724
[TBL] [Abstract][Full Text] [Related]
10. Subclinical Atherosclerosis Is Associated with Discrepancies in BAFF and APRIL Levels and Altered Breg Potential of Precursor-like Marginal Zone B-Cells in Long-Term HIV Treated Individuals.
Aranguren M; Doyon-Laliberté K; El-Far M; Chartrand-Lefebvre C; Routy JP; Barril JG; Trottier B; Tremblay C; Durand M; Poudrier J; Roger M;
Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679926
[TBL] [Abstract][Full Text] [Related]
11. Excess BAFF Alters NR4As Expression Levels and Breg Function of Human Precursor-like Marginal Zone B-Cells in the Context of HIV-1 Infection.
Doyon-Laliberté K; Aranguren M; Byrns M; Chagnon-Choquet J; Paniconi M; Routy JP; Tremblay C; Quintal MC; Brassard N; Kaufmann DE; Poudrier J; Roger M
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499469
[TBL] [Abstract][Full Text] [Related]
12. Marginal Zone B-Cell Populations and Their Regulatory Potential in the Context of HIV and Other Chronic Inflammatory Conditions.
Doyon-Laliberté K; Aranguren M; Poudrier J; Roger M
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328792
[TBL] [Abstract][Full Text] [Related]
13. Excess BAFF May Impact HIV-1-Specific Antibodies and May Promote Polyclonal Responses Including Those from First-Line Marginal Zone B-Cell Populations.
Doyon-Laliberté K; Aranguren M; Chagnon-Choquet J; Batraville LA; Dagher O; Richard J; Paniconi M; Routy JP; Tremblay C; Quintal MC; Brassard N; Kaufmann DE; Finzi A; Poudrier J; Roger M
Curr Issues Mol Biol; 2023 Dec; 46(1):25-43. PubMed ID: 38275663
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
